AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3909323 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (1-g or 2-g intravenous doses, three times daily for at least five days)
Number of subjects: 226
Study 3909323 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 226
Study 3909323 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (administered to a group of 34 patients)
Number of subjects: 226
Study 31243574 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain (group A, n = 69)
Number of subjects: 136
Study 31243574 — intervention group
Group type: COMPARATOR
Intervention: No drain (group B, n = 67)
Number of subjects: 136
Study 29415754 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanxinning tablet (GXNT) plus aspirin for 12 months
Number of subjects: 3600
Study 29415754 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone for 12 months
Number of subjects: 3600
Study 29415754 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanxinning tablet (GXNT) plus aspirin
Number of subjects: 3600
Study 29415754 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3600
Study 27488394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ramosetron
Number of subjects: 114
Study 27488394 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 114
Study 25399975 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong Injection
Number of subjects: 120
Study 23597225 — intervention group
Group type: EXPERIMENTAL
Intervention: APF (1.23% acidulated phosphate fluoride gel)
Number of subjects: 0
Study 23597225 — intervention group
Group type: EXPERIMENTAL
Intervention: NNaF (2% neutral sodium fluoride gel)
Number of subjects: 0
Study 23597225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both APF and NNaF
Number of subjects: 0
Study 21038764 — intervention group
Group type: EXPERIMENTAL
Intervention: kiR-Plus intervention in 5th grade
Number of subjects: 1984
Study 21038764 — intervention group
Group type: EXPERIMENTAL
Intervention: kiR-AE intervention in both 5th and 7th grades
Number of subjects: 1984
Study 21038764 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison schools' programming)
Number of subjects: 1984
Study 18218825 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable peroneal nerve stimulator (FES) for 6 months
Number of subjects: 29
Study 18218825 — intervention group
Group type: COMPARATOR
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 29
Study 16734505 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene cream group
Number of subjects: 1136
Study 16734505 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating group
Number of subjects: 1136
Study 16734505 — intervention group
Group type: COMPARATOR
Intervention: Vehicle group
Number of subjects: 1136
Study 16734505 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene cream vs Vehicle
Number of subjects: 1136
Study 16734505 — intervention group
Group type: COMPARATOR
Intervention: Alternating vs Vehicle
Number of subjects: 1136
Study 16734505 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene cream vs Vehicle (adverse reactions)
Number of subjects: 1136
Study 16734505 — intervention group
Group type: COMPARATOR
Intervention: Alternating vs Vehicle (adverse reactions)
Number of subjects: 1136
Study 14601366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg intravenous upon anesthetic induction, every 4 hours during surgery, and every 8 hours for 48 hours post-surgery
Number of subjects: 20
Study 14601366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 20
Study 14601366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TA)
Number of subjects: 20
Study 11458309 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperament and Character Inventory (TCI)
Number of subjects: 156
Study 9510902 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based programs focusing on adolescent health problems
Number of subjects: 11
Study 9510902 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health promotion projects
Number of subjects: 11
Study 8167383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 15
Study 8167383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2892988 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement administered for eight months
Number of subjects: 90
Study 2892988 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for eight months
Number of subjects: 90
Study 2892988 — intervention group
Group type: COMPARATOR
Intervention: No tablets taken
Number of subjects: 90
Study 31758663 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning collaborative intervention group focused on a treat‐to‐target approach
Number of subjects: 554
Study 31758663 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 554
Study 31758663 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning collaborative intervention group
Number of subjects: 554
Study 31664959 — intervention group
Group type: EXPERIMENTAL
Intervention: SmokeFree Buddy app (intervention group)
Number of subjects: 0
Study 31664959 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific app mentioned)
Number of subjects: 0
Study 28485023 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rituximab (HD-R) 1000 mg/m2
Number of subjects: 93
Study 28485023 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose rituximab (SD-R) 375 mg/m2
Number of subjects: 93
Study 28485023 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in complete remission (CR) before ASCT
Number of subjects: 93
Study 28485023 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≤2 lines of treatment prior to SCT
Number of subjects: 93
Study 26362286 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 500 mg orally once daily (with dose escalation by 500‐mg increments every 13 weeks, ending with 1,000 mg twice daily)
Number of subjects: 119
Study 26362286 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol treatment
Number of subjects: 119
Study 26362286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 23870300 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab therapy
Number of subjects: 353
Study 23870300 — intervention group
Group type: COMPARATOR
Intervention: Quarterly ranibizumab therapy
Number of subjects: 353
Study 21608442 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-Inositol 2 g twice a day
Number of subjects: 84
Study 21608442 — intervention group
Group type: COMPARATOR
Intervention: D-chiro inositol 0.6 g twice a day
Number of subjects: 84
Study 19366435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of M-M-RvaxPro and VARIVAX
Number of subjects: 752
Study 19366435 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration of M-M-RvaxPro and VARIVAX
Number of subjects: 752
Study 19366435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration
Number of subjects: 752
Study 19366435 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration
Number of subjects: 752
Study 19366435 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes of administration
Number of subjects: 752
Study 16482079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish protein meal
Number of subjects: 23
Study 16482079 — intervention group
Group type: COMPARATOR
Intervention: Beef protein meal
Number of subjects: 23
Study 15516942 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 117
Study 15516942 — intervention group
Group type: COMPARATOR
Intervention: Control (no G-CSF)
Number of subjects: 117
Study 11346153 — intervention group
Group type: EXPERIMENTAL
Intervention: Descalating dose of interferon-alpha-2a; six million units thrice weekly for 24 weeks followed by 3 MIU 3x for 24 weeks
Number of subjects: 32
Study 11346153 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha-2a (3 million units thrice weekly for 24 weeks) plus ribavirin (1,000 mg/day for 12 weeks)
Number of subjects: 32
Study 9214527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 1.5 mg/d
Number of subjects: 264
Study 9214527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 3.0 mg/d
Number of subjects: 264
Study 9214527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 4.5 mg/d
Number of subjects: 264
Study 9214527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 6.0 mg/d
Number of subjects: 264
Study 9214527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 9214527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (all doses combined)
Number of subjects: 264
Study 7525517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (Group C)
Number of subjects: 41
Study 7525517 — intervention group
Group type: COMPARATOR
Intervention: Nonondansetron antiemetics (Group B)
Number of subjects: 41
Study 7525517 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment antiemetics (Group A)
Number of subjects: 41
Study 31262767 — intervention group
Group type: COMPARATOR
Intervention: SPR741, 5 to 800 mg single doses; 50 to 600 mg multiple doses every 8 hours for 14 days
Number of subjects: 0
Study 31262767 — intervention group
Group type: COMPARATOR
Intervention: SPR741, 400 mg single dose
Number of subjects: 0
Study 31262767 — intervention group
Group type: EXPERIMENTAL
Intervention: SPR741, up to 1,800 mg/day
Number of subjects: 0
Study 31262767 — intervention group
Group type: EXPERIMENTAL
Intervention: SPR741, multiple doses
Number of subjects: 0
Study 30381621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous l-carnitine
Number of subjects: 45
Study 30381621 — intervention group
Group type: COMPARATOR
Intervention: Intravenous branched-chain amino acids (BCAA)
Number of subjects: 45
Study 30381621 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral l-carnitine supplementation
Number of subjects: 45
Study 30381621 — intervention group
Group type: COMPARATOR
Intervention: Conventional agents (lactulose and non-absorbable antibiotics)
Number of subjects: 45
Study 30381621 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood ammonia levels
Number of subjects: 45
Study 27106272 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 44
Study 27106272 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment
Number of subjects: 44
Study 25282165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk surgical patients (HR)
Number of subjects: 698
Study 25282165 — intervention group
Group type: COMPARATOR
Intervention: Non-high-risk surgical patients (non-HR)
Number of subjects: 698
Study 22284318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 45
Study 22284318 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator guidance
Number of subjects: 45
Study 19577936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pio plus the American Diabetes Association diet (Pio+ADA)
Number of subjects: 51
Study 19577936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pio plus a portion control weight loss diet (Pio+PC)
Number of subjects: 51
Study 19577936 — intervention group
Group type: COMPARATOR
Intervention: metformin plus ADA diet (Met+ADA)
Number of subjects: 51
Study 18922381 — intervention group
Group type: EXPERIMENTAL
Intervention: Waon therapy
Number of subjects: 188
Study 18922381 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study 16022970 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombus-aspiration
Number of subjects: 99
Study 16022970 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 99
Study 12458654 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 or 16 mg
Number of subjects: 968
Study 10520057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) aqueous nasal spray, 200 microg once daily
Number of subjects: 24
Study 10520057 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine (LEV) nasal spray, 200 microg twice daily
Number of subjects: 24
Study 10520057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) nasal spray
Number of subjects: 24
Study 8559985 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (100 mcg intravaginally)
Number of subjects: 100
Study 8559985 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (2‐32 mU/min IV)
Number of subjects: 100
Study 1791485 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (an angiotensin converting enzyme inhibitor)
Number of subjects: 13000
Study 30203840 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) prevention trial
Number of subjects: 517
Study 30203840 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 517
Study 28830204 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory‐driven, home‐based, self‐help parenting program
Number of subjects: 577
Study 28830204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 577
Study 27426699 — intervention group
Group type: EXPERIMENTAL
Intervention: CES with 200 mg caffeine (CAF2)
Number of subjects: 15
Study 27426699 — intervention group
Group type: EXPERIMENTAL
Intervention: CES with 100 mg caffeine (CAF1)
Number of subjects: 15
Study 27426699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study 25122031 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week individually tailored, motivationally matched exercise intervention
Number of subjects: 260
Study 25122031 — intervention group
Group type: COMPARATOR
Intervention: Health and wellness intervention
Number of subjects: 260
Study 22982471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (480 mg/day for 6 months)
Number of subjects: 0
Study 22982471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (960 mg/day for 5 weeks)
Number of subjects: 0
Study 22982471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (single and 14-day repeat dosing in rats and dogs)
Number of subjects: 0
Study 22982471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (highest dose level in dogs)
Number of subjects: 0
Study 22982471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (rat and dog studies)
Number of subjects: 0
Study 22982471 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse mutation assays
Number of subjects: 0
Study 22982471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzogenol® pine bark extract (general findings)
Number of subjects: 0
Study 19889523 — intervention group
Group type: COMPARATOR
Intervention: Primary care
Number of subjects: 150
Study 19889523 — intervention group
Group type: COMPARATOR
Intervention: Specialized care
Number of subjects: 150
Study 19889523 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 150
Study 18001210 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg purified isoflavones for 12 weeks
Number of subjects: 53
Study 18001210 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 53
Study 15533544 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone support with nicotine patches
Number of subjects: 330
Study 15533544 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patches (control condition)
Number of subjects: 330
Study 12015500 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol 12 and 24 hours before surgery
Number of subjects: 204
Study 12015500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 12015500 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol
Number of subjects: 204
Study 10213125 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5mg twice a day)
Number of subjects: 34
Study 10213125 — intervention group
Group type: COMPARATOR
Intervention: Control (no calcitriol)
Number of subjects: 34
Study 8574714 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice daily for 1 week (Phase 1)
Number of subjects: 200
Study 8574714 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole twice daily for 1 week (Group A)
Number of subjects: 200
Study 8574714 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole daily for 1 week (Group B)
Number of subjects: 200
Study 8574714 — intervention group
Group type: COMPARATOR
Intervention: No omeprazole for 1 week (Group C)
Number of subjects: 200
Study 2192985 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP 50 mg/mq + alizapride
Number of subjects: 75
Study 2192985 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP 50 mg/mq + metoclopramide
Number of subjects: 75
Study 2192985 — intervention group
Group type: COMPARATOR
Intervention: CDDP 50 mg/mq + placebo
Number of subjects: 75
Study 393299 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 56
Study 393299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 393299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preparations containing oestrogen and progestogen
Number of subjects: 56
Study 29437489 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text message reminders for 30 days
Number of subjects: 41
Study 29437489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 41
Study 29437489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received electronic sensors to measure ICS use
Number of subjects: 41
Study 29437489 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers who completed the acceptability survey
Number of subjects: 41
Study 29437489 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence trajectories
Number of subjects: 41
Study 30388775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate and potassium bicarbonate fortified with minerals, ingested twice a day over a nine-day training period.
Number of subjects: 26
Study 30388775 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 26
Study 27468541 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Traditional Chinese Medicine (TCM) with basic treatment
Number of subjects: 240
Study 27468541 — intervention group
Group type: COMPARATOR
Intervention: Placebo with basic treatment
Number of subjects: 240
Study 25117155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sanitiser provision in classrooms
Number of subjects: 2443
Study 25117155 — intervention group
Group type: COMPARATOR
Intervention: Control (usual hand hygiene education only)
Number of subjects: 2443
Study 22893135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide 20 mg
Number of subjects: 601
Study 22893135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study 19373107 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification alone
Number of subjects: 72
Study 19373107 — intervention group
Group type: COMPARATOR
Intervention: Combined phaco-trabeculectomy
Number of subjects: 72
Study 18076264 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertec device with squat jump protocol
Number of subjects: 95
Study 18076264 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertec device
Number of subjects: 95
Study 18076264 — intervention group
Group type: COMPARATOR
Intervention: Just Jump device
Number of subjects: 95
Study 18076264 — intervention group
Group type: COMPARATOR
Intervention: Countermovement jump protocol
Number of subjects: 95
Study 18076264 — intervention group
Group type: COMPARATOR
Intervention: Squat jump protocol
Number of subjects: 95
Study 16150197 — intervention group
Group type: EXPERIMENTAL
Intervention: Naohuandan (NHD), 4 capsules each time, 3 times daily for 3 months
Number of subjects: 58
Study 16150197 — intervention group
Group type: COMPARATOR
Intervention: Piracetam, 1.6 g each time, 3 times daily for 3 months
Number of subjects: 58
Study 16150197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage NHD
Number of subjects: 58
Study 16150197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage NHD
Number of subjects: 58
Study 16150197 — intervention group
Group type: COMPARATOR
Intervention: Model group (no treatment)
Number of subjects: 58
Study 12871256 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once per week for 6 months
Number of subjects: 110
Study 12871256 — intervention group
Group type: COMPARATOR
Intervention: Placebo once per week for 6 months
Number of subjects: 110
Study 10812040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 10
Study 10812040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8642144 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedural subgingival irrigation and rinsing with an antiseptic mouthrinse
Number of subjects: 0
Study 8642144 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 0
Study 1619099 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior management training (n = 20)
Number of subjects: 61
Study 1619099 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving and communication training (n = 21)
Number of subjects: 61
Study 1619099 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural family therapy (n = 20)
Number of subjects: 61
Study 1619099 — intervention group
Group type: COMPARATOR
Intervention: All treatments combined
Number of subjects: 61
Study 6531953 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent subunit influenza virus vaccine
Number of subjects: 0
Study 6531953 — intervention group
Group type: COMPARATOR
Intervention: Trivalent split vaccine
Number of subjects: 0
Study 6531953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 0
Study 31469675 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C-augmented phacotrabeculectomy
Number of subjects: 63
Study 31469675 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 63
Study 31469675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63